{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:57:05Z","timestamp":1787961425809,"version":"build-2784847793"},"reference-count":47,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Osteoporosis is a common chronic condition after menopause that increases the risk of fractures. In South Korea, the prevalence of osteoporosis among adults aged 50 and older is 22.4%, with 94.4% of treated patients being women, highlighting its significant impact on postmenopausal health. In this study, we examine the sales trends of osteoporosis medications in Korea from 2018 to 2023 to understand current usage patterns and market dynamics. Materials and Methods: This study is a retrospective analysis based on pre-recorded sales data from Intercontinental Marketing Services (IMS). Data covering a five-year period (2018\u20132023) were analyzed to examine the sales trends of osteoporosis medications, including bisphosphonates, selective estrogen receptor modulators (SERMs), parathyroid hormone analogs, denosumab, romosozumab, and others. Romosozumab, approved in November 2019, was included in the analysis. Given the nature of this study, no direct patient data or clinical interventions were involved. Results: The total market size for osteoporosis medications in South Korea reached USD 285.42 million in 2023, reflecting a 15.3% increase from 2022. Bisphosphonates, previously the dominant therapy, experienced an 11% decline in market share over five years. Meanwhile, denosumab, a receptor activator of the nuclear factor-\u03baB ligand inhibitor, showed a remarkable growth rate of 957.6% from 2018 to 2023, surpassing bisphosphonates in their market share. Romosozumab, a newly introduced anabolic agent, accounted for 7.4% of the market, with sales increasing by 59% in 2023. Conclusions: This analysis revealed major shifts in treatment preferences, with newer drugs like denosumab and romosozumab gaining prominence over traditional bisphosphonates. These trends highlight the increasing clinical adoption of anabolic agents for high-risk patients and the impact of expanded reimbursement policies on osteoporosis management. Given the increasing use of advanced therapies, it is essential to monitor treatment access, patient adherence, and long-term clinical outcomes. Understanding these sales trends can aid healthcare professionals and policymakers in optimizing osteoporosis treatment strategies and ensuring better patient care.<\/jats:p>","DOI":"10.3390\/medicina61050805","type":"journal-article","created":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T20:42:37Z","timestamp":1746391357000},"page":"805","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Five-Year Sales Trends of Osteoporosis Medications in Korea: A Market Analysis Based on IMS Health Sales Audit Data (2018\u20132023)"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0756-2439","authenticated-orcid":false,"given":"Jung Yoon","family":"Park","sequence":"first","affiliation":[{"name":"Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8186-6230","authenticated-orcid":false,"given":"Youn-Jee","family":"Chung","sequence":"additional","affiliation":[{"name":"Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4492-0768","authenticated-orcid":false,"given":"Mee-Ran","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2167-7243","authenticated-orcid":false,"given":"Jae-Yen","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (1992, January 22\u201325). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO study group [meeting held in Rome from 22 to 25 June 1992]. Proceedings of the Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis: Report of a WHO Study Group, Rome, Italy."},{"key":"ref_2","unstructured":"NIH CNcs (2000). Osteoporosis prevention, diagnosis, and therapy. NIH Consens. Statement, 17, 1\u201345."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos. Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bone.2005.11.024","article-title":"Osteoporosis: A still increasing prevalence","volume":"38","author":"Reginster","year":"2006","journal-title":"Bone"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.11005\/jbm.2020.27.4.281","article-title":"Osteoporosis and osteoporotic fracture fact sheet in Korea","volume":"27","author":"Ahn","year":"2020","journal-title":"J. Bone Metab."},{"key":"ref_6","unstructured":"Health Insurance Review & Assessment Service (HIRA) (2023). Stc Illness Information View, Health Insurance Review & AssessmentService (HIRA)."},{"key":"ref_7","unstructured":"National Health Insurance Service (2020). 2015\u20132019 Statistical Reports on Osteoporosis, National Health Insurance Service."},{"key":"ref_8","first-page":"e29367","article-title":"Postmenopausal osteoporosis: A literature review","volume":"14","author":"Bhatnagar","year":"2022","journal-title":"Cureus"},{"key":"ref_9","unstructured":"Zaheer, S., and LeBoff, M.S. (2022). Osteoporosis: Prevention and treatment. Endotext, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279073\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","article-title":"Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024","volume":"39","author":"Cosman","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"ref_11","unstructured":"World Health Organization (2020). Coronavirus Disease 2019 (COVID-19) Situation Report\u201346, World Health Organization."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1056\/NEJMms2009984","article-title":"The untold toll\u2014The pandemic\u2019s effects on patients without Covid-19","volume":"382","author":"Rosenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Voulgaridou, G., Papadopoulou, S.K., Detopoulou, P., Tsoumana, D., Giaginis, C., Kondyli, F.S., Lymperaki, E., and Pritsa, A.J.D. (2023). Vitamin D and calcium in osteoporosis, and the role of bone turnover markers: A narrative review of recent data from RCTs. Diseases, 11.","DOI":"10.3390\/diseases11010029"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lordan, R.J.N. (2021). Notable developments for vitamin D amid the COVID-19 pandemic, but caution warranted overall: A narrative review. Nutrients, 13.","DOI":"10.3390\/nu13030740"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1749-6632.2010.05768.x","article-title":"Bisphosphonate-related osteonecrosis of the jaw: An overview","volume":"1218","author":"Ruggiero","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_16","first-page":"1","article-title":"Genetic risk factors for atypical femoral fractures (AFFs): A systematic review","volume":"2","author":"Nguyen","year":"2018","journal-title":"J. Bone Miner. Res. Plus"},{"key":"ref_17","unstructured":"Korean Society for Bone and Mineral Research (2020). 2020 Physician\u2019s Guide for Osteoporosis, Korean Society for Bone and Mineral Research."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Benchimol, E.I., Smeeth, L., Guttmann, A., Harron, K., Moher, D., Petersen, I., S\u00f8rensen, H.T., von Elm, E., and Langan, S.M. (2015). The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med., 12.","DOI":"10.1371\/journal.pmed.1001885"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1017\/S0266462313000160","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) statement","volume":"29","author":"Husereau","year":"2013","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_20","first-page":"46","article-title":"An overview and management of osteoporosis","volume":"4","year":"2016","journal-title":"Eur. J. Rheumatol."},{"key":"ref_21","first-page":"873","article-title":"Osteoporosis in older adults","volume":"104","author":"Johnston","year":"2020","journal-title":"Med. Clin."},{"key":"ref_22","unstructured":"National Health Insurance Service Ilsan Hospital Institute of Health Insurance and Clinical Research (2020). A Study on the Osteoporotic Compression Fracture Occurrence Frequency According to the Trend of Osteoporosis Treatment and Treatment of Osteoporotic Patients in Korea, National Health Insurance Service Ilsan Hospital Institute of Health Insurance and Clinical Research."},{"key":"ref_23","unstructured":"Korea Health Industry Development Institute (KHIDI) (2018). Global market analysis of osteoporosis treatment. KHIDI Brief, 253."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.11005\/jbm.2021.28.3.201","article-title":"The Trend in the Sales of Menopausal Hormone and Other Osteoporosis Medications in South Korea from 2016 to 2019","volume":"28","author":"Lee","year":"2021","journal-title":"J. Bone Metab."},{"key":"ref_25","unstructured":"Pfizer Korea (2025, April 23). Announcement Regarding the Voluntary Recall of Duavive Tablets (0.45\/20mg, Lot Numbers: T34122, T42330, W78858, W78860, X34636, AG6437, AG6438, CG3243, CW7990, DC5278). Available online: https:\/\/www.pfizer.co.kr\/media\/%ED%99%94%EC%9D%B4%EC%9E%90-%EC%86%8C%EC%8B%9D\/%EB%93%80%EC%95%84%EB%B9%84%EB%B8%8C%EC%A0%95-04520mg-%EC%A0%9C%EC%A1%B0%EB%B2%88%ED%98%B8-t34122-t42330-w78858-w78860-x34636-ag6437-ag6438-cg3243-cw7990-dc5278-%EC%9E%90%EC%A7%84%ED%9A%8C%EC%88%98%EC%9D%98-%EA%B1%B4."},{"key":"ref_26","unstructured":"Health Insurance Review & Assessment Service (HIRA) (2019). Criteria for Reimbursement of Denosumab, Health Insurance Review & Assessment Service (HIRA))."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"25103","DOI":"10.1074\/jbc.R109.041087","article-title":"Cellular and molecular mechanisms of bone remodeling","volume":"285","author":"Raggatt","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_31","first-page":"411","article-title":"FDA approves first-in-class osteoporosis drug","volume":"18","author":"Mullard","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.coph.2015.03.005","article-title":"Parathyroid hormone: Anabolic and catabolic actions on the skeleton","volume":"22","author":"Silva","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1759720X18775936","article-title":"The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis","volume":"10","author":"Langdahl","year":"2018","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/jbmr.3439","article-title":"Romosozumab FRAME study: A post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome","volume":"33","author":"Cosman","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis\u20142020 Update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr. Pract."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eprac.2021.01.019","article-title":"AACE\/ACE clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update: Risk stratification and intervention thresholds","volume":"27","author":"Chandran","year":"2021","journal-title":"Endocr. Pract."},{"key":"ref_39","unstructured":"Centers for Medicare & Medicaid Services (CMS) (2024, December 20). Medicare Part B coverage for Romosozumab Following FDA Approval, Available online: https:\/\/www.cms.gov."},{"key":"ref_40","unstructured":"Amgen (2019). Evenity (Romosozumab) Receives Approval in Japan for the Treatment of Osteoporosis in Patients at High Risk of Fracture, Amgen. Available online: https:\/\/www.amgen.com\/newsroom\/press-releases\/2019\/01\/evenity-romosozumab-receives-approval-in-japan-for-the-treatment-of-osteoporosis-in-patients-at-high-risk-of-fracture."},{"key":"ref_41","unstructured":"Japanese Society for Bone and Mineral Research (JSBMR) (2017). Development of the Fracture Risk Assessment Tool (FRAX) in Japan. Endocr. J., 65, 109\u2013117. Available online: https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/65\/2\/65_EJ17-0331\/_article\/-char\/ja."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00774-013-0444-y","article-title":"Osteoporosis and treatments in Japan: Management for preventing subsequent fractures","volume":"31","author":"Nojiri","year":"2013","journal-title":"J. Bone Miner. Metab."},{"key":"ref_43","unstructured":"U.S. Food and Drug Administration (2024, December 20). FDA Approves New Treatment for Osteoporosis in Postmenopausal Women at High Risk for Fracture, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-osteoporosis-postmenopausal-women-high-risk-fracture."},{"key":"ref_44","unstructured":"Ministry of Food and Drug Safety (MFDS) (2025, January 23). Approval of Romosozumab (Evenity) for Osteoporosis Treatment, Available online: https:\/\/www.mfds.go.kr."},{"key":"ref_45","unstructured":"Health Insurance Review & Assessment Service (HIRA) (2024). (n.d.) Reimbursement Criteria for Romosozumab [\ub85c\ubaa8\uc18c\uc8fc\ub9d9 \uae09\uc5ec \uae30\uc900], Health Insurance Review & Assessment Service (HIRA). Available online: https:\/\/www.hira.or.kr\/rc\/insu\/insuadtcrtr\/InsuAdtCrtrList.do."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.clinthera.2008.04.009","article-title":"Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: A 12-month, open-label, prospective evaluation","volume":"30","author":"Lewiecki","year":"2008","journal-title":"Clin. Ther."},{"key":"ref_47","unstructured":"Ministry of Health and Welfare (MOHW) (2025, January 23). Revision of Reimbursement Criteria for Osteoporosis Medications, Available online: https:\/\/www.mohw.go.kr\/boardDownload.es?bid=0026&list_no=1482116&seq=7."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/5\/805\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:22:00Z","timestamp":1760030520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/5\/805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["medicina61050805"],"URL":"https:\/\/doi.org\/10.3390\/medicina61050805","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]}}}